Alogabat

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome. It is taken by mouth. As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome. It is under development by Roche.

GABAA receptor modulator

Pharmaceutical compound

Alogabat

Clinical data
Other names	GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773
Routes of administration	Oral[1]
Drug class	α5 subunit-containing GABAA receptor positive allosteric modulator
Identifiers
IUPAC name 6-[[5-methyl-3-(6-methylpyridin-3-yl)-1,2-oxazol-4-yl]methoxy]-N-(oxan-4-yl)pyridazine-3-carboxamide
CAS Number	2230009-48-8
PubChem CID	134588268
DrugBank	DB18708
ChemSpider	115006746
UNII	0HPA4GK3UH
KEGG	D12382
ChEMBL	ChEMBL5095259
Chemical and physical data
Formula	C21H23N5O4
Molar mass	409.446 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NC=C(C=C1)C2=NOC(=C2COC3=NN=C(C=C3)C(=O)NC4CCOCC4)C
InChI InChI=1S/C21H23N5O4/c1-13-3-4-15(11-22-13)20-17(14(2)30-26-20)12-29-19-6-5-18(24-25-19)21(27)23-16-7-9-28-10-8-16/h3-6,11,16H,7-10,12H2,1-2H3,(H,23,27) Key:ACZCJTHHWMBFKC-UHFFFAOYSA-N

Alogabat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names RG-7816 and RO7017773) is an α₅ subunit-containing GABA_A receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.^[1][2][3][4] It is taken by mouth.^[1]

As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.^[1][2] It is under development by Roche.^[1][2]

See also

[edit]

• Darigabat

References

[edit]

1. ^ ^{a b c d e} "Alogabat - Genentech". AdisInsight. 28 June 2024. Retrieved 29 October 2024.
2. ^ ^{a b c} "Delving into the Latest Updates on RG-7816 with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
3. ^ Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA_AR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. hdl:11365/1214874. PMID 31738537.
4. ^ Stevens EB, Stephens GJ (2024). "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e